Besides, the administration of the glycoprotein UK279,276, a CD11/CD18 integrin antagonist, within 6 hours of symptom onset did not improve stroke outcome in stroke patients receiving recombinant tPA-induced thrombolysis, as compared to patients receiving tPA alone (17). Here, PLAT is linked to stroke disorder.